Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Low dose HP-hMG in an antagonist protocol for IVF in ovulatory and anovulatory patients with high AMH

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. The impact of gastric bypass surgery on sex hormones and menstrual cycles in premenopausal women

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Atrial natriuretic peptide, copeptin and adrenomedullin levels in polycystic ovary syndrome: a case-control study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Left-right differences in ovarian volume and antral follicle count in 1423 women of reproductive age

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Selective use of corifollitropin for controlled ovarian stimulation for IVF in patients with low anti-Müllerian hormone

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Cumulative live birth rate prognosis based on the number of aspirated oocytes in previous ART cycles

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. A randomized controlled trial of AMH-based individualized FSH dosing in a GnRH antagonist protocol for IVF

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Status one year after fertility assessment and counselling in women of reproductive age-a qualitative study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Autotransplantation of fragmented ovarian cortical tissue: a laparoscopic demonstration

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Women with high-AMH levels have an increased risk of ovarian hyperstimulation syndrome (OHSS). Studies have suggested that highly purified menotropin (HP-hMG) Menopur® reduces the risk. We, therefore, studied use of low-dose (112.5 IU/day) HP-hMG in ovulatory and anovulatory patients with high AMH (>32 pmol/L). The primary endpoint was the distribution of patients with appropriate, excessive, and inadequate response (5-14, ≥15, and ≤4 oocytes). Another endpoint was frequency of OHSS. Totally 115 women were included and 78 (67.8%) had an appropriate, 8 (7.0%) an excessive, and 29 (25.2%) an inadequate response. The number of oocytes was independent on AMH levels and ovulatory status but declined significantly with increasing bodyweight (R2 = 0.07, p < .01). The ongoing pregnancy rate per started cycle was 47.0%. Three (2.6%) developed OHSS, two had cancelation of the cycle and seven patients had GnRH agonist triggering to prevent OHSS. Selective use of a low dose of HP-hMG in patients with high levels of AMH provides 5-14 oocytes in more than two-thirds of the patients and is safe with low risk of OHSS. The number of aspirated oocytes was independent of AMH levels and ovulatory status, but inversely related to body weight.

OriginalsprogEngelsk
TidsskriftGynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
Vol/bind34
Udgave nummer7
Sider (fra-til)623-626
Antal sider4
ISSN0951-3590
DOI
StatusUdgivet - jul. 2018

ID: 56415280